BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
Abstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in M...
Saved in:
| Main Authors: | Huijian Zheng, Huajian Xian, Wenjie Zhang, Chaoqun Lu, Renyao Pan, Han Liu, Zhenshu Xu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | Journal of Hematology & Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13045-025-01675-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01) -
MENIN inhibitor-based therapy in acute leukemia: latest updates from the 2024 ASH annual meeting
by: Jiewen Sun, et al.
Published: (2025-05-01) -
Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
by: Ning An, et al.
Published: (2025-05-01) -
Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
by: Lili Zhou, et al.
Published: (2025-05-01) -
Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01)